IPAROMLIMAB AND TUVONRALIMAB INJECTION
Clinical trials for IPAROMLIMAB AND TUVONRALIMAB INJECTION explained in plain language.
Never miss a new study
Get alerted when new IPAROMLIMAB AND TUVONRALIMAB INJECTION trials appear
Sign up with your email to follow new studies for IPAROMLIMAB AND TUVONRALIMAB INJECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune combo tackles Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis early-phase trial tests a combination of three treatments for advanced colorectal cancer that has not responded to standard therapies. The approach uses the patient's own immune cells (DC-CIK), a targeted drug (regorafenib), and a bispecific antibody to boost the immune syst…
Matched conditions: IPAROMLIMAB AND TUVONRALIMAB INJECTION
Phase: EARLY_PHASE1 • Sponsor: JIANG LONGWEI • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cocktail therapy targets tough liver cancer with blood clot
Disease control Recruiting nowThis study tests a combination of an experimental immunotherapy (QL1706), a blood vessel blocker (bevacizumab), and chemotherapy given directly into the liver artery for people with advanced liver cancer that has caused a clot in the main portal vein. The goal is to see if this a…
Matched conditions: IPAROMLIMAB AND TUVONRALIMAB INJECTION
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC